Durvalumab Alone or With Tremelimumab in Refractory Germ Cell Tumors

NCT03081923 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

36

Enrollment

OTHER

Sponsor class

Stopped loss of accrual

Conditions

Germ Cell Tumor

Interventions

DRUG: Durvalumab
DRUG: Tremelimumab

Sponsor

Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

Collaborators

[object Object]